Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer

Phase 1

Completed

• Conditions: Advanced Solid Cancers
• Interventions: Drug: CKD-810, Taxotere inj.

• Registration Number: NCT01019941
• Lead Sponsor: Chong Kun Dang Pharmaceutical

Brief Summary

The purpose of this study is to evaluate safety and the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer.

Detailed Description

This is a Phase III study designed to evaluate the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer. This study will also assess the safety of the docetaxel in advanced solid cancer patients.

Study Timeline

• Study Start: 2009-08
• Study First Submitted: 2009-11-23
• Study First Submitted QC: 2009-11-24
• Study First Posted: 2009-11-25
• Primary Completion: 2010-08
• Status Verified: 2010-12
• Study Completion: 2010-12
• Last Update Submitted: 2010-12-15
• Last Update Posted: 2010-12-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

• Patient is greater than 18 years of age

• Advanced solid tumor

  • locally advanced or metastatic breast cancer which docetaxel alone therapy was adequate
  • locally advanced or metastatic non-small cell lung cancer which docetaxel alone therapy was adequate
  • locally advanced or metastatic other malignant tumor which docetaxel alone therapy was adequate

• Patient has a life expectancy of at least 3 months

• Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

• Absolute neutrophil count ≥ 1,500/㎣

• Platelet count ≥ 100,000/㎣

• Hemoglobin ≥ 9.0g/dL

• Total Bilirubin ≤ 1.5 X ULN

• Alkaline Phosphatase ≤ 2.5 X ULN

• AST/ALT ≤ 2.0 X ULN

• Serum creatinine ≤ 1.5 X ULN or Creatinine clearance ≥ 60mL/min(Cockcroft equation)

• Patients should voluntarily sign a written informed consent before study entry

Read More

Exclusion Criteria

• If present, any active bacterial infection that have to parenteral antibiotic therapy. Patients may be included if their infection has resolved to totally or controlled state
• Brain metastasis with neurologic symptom
• History of unstable cardiac arrhythmia, congestive heart failure or myocardial infarction within 6 months
• Known to test positive for HIV or hepatitis B or C
• Use of inducers or inhibitors of CYP3A4 within 2 weeks prior to the first dose of study medication. (Patients may be included if the patients who need to intake the medication such as cimetidine was keep the same dose continuously at 1 cycle and 2 cycle)
• Peripheral neuropathy ≥ Grade 2
• known resistant or uncontrolled severe hypersensitivity to docetaxel
• History of hypersensitivity reaction to Polysorbate 80
• The female patients of pregnancy, breast feeding or childbearing potential. And the patients has not laboratory result or the result was a positive serum pregnancy test, also Patients (M/F) with reproductive potential not implementing adequate contraceptive measurements. (In case of menopausal women, keeping menopause at least 12 months. All sexually active male patients must agree to use adequate methods of birth control throughout the study)
• Administration of any other tumor therapy, including chemotherapy, radiotherapy, and immunotherapy within 4 weeks before the beginning of study treatment. Patients may be included if the radiotherapy was conducted to relieve symptoms and that symptoms recovered to grade 1
• treated with any investigational drugs within 4 weeks before the beginning of study treatment
• Must be treated concurrent administration of other anti-cancer medicine
• Not able to participate to the study, at the discretion of the investigator

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.	CKD-810, Taxotere inj.	-
1st cycle:Taxotere inj.-> 2nd cycle:CKD-810	CKD-810, Taxotere inj.	-

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics of CKD-810 and Taxotere inj.	2 Cycles

Secondary Outcome Measures

Name	Time	Method
Safety of CKD-810 and Taxotere inj.	2 Cycles

Trial Locations

Locations (7)

Ajou University Hospital; 🇰🇷 Suwon, Korea, Republic of

The Korea University Anam Hospital; 🇰🇷 Seoul, Korea, Republic of

Gachon University Gil Hospital; 🇰🇷 Inchon, Korea, Republic of

Yeoungnam University Hospital; 🇰🇷 Taegu, Korea, Republic of

Dongsan Medical Center, Keimyung University; 🇰🇷 Taegu, Korea, Republic of

Ulsan University Hospital; 🇰🇷 Ulsan, Korea, Republic of

The Catholic university of KOREA, Seoul ST. Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of